BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases

The development of mutant BRAF inhibitors has improved the outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes resulting in complete tumor regression, the majority of melanomas become resistant. To study resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigore, Florina, Yang, Hana, Hanson, Nicholas D., VanBrocklin, Matthew W., Sarver, Aaron L., Robinson, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338995/
https://www.ncbi.nlm.nih.gov/pubmed/32629178
http://dx.doi.org/10.1016/j.neo.2020.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338995/
https://www.ncbi.nlm.nih.gov/pubmed/32629178
http://dx.doi.org/10.1016/j.neo.2020.06.006

Ejemplares similares